Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach
To determine the incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders (25-35 follicles with a diameter of ≥12 mm on day of triggering) who received a gonadotropin-releasing hormone (GnRH) agonist to trigger final follicular maturation. We used individual data from wo...
Gespeichert in:
| Veröffentlicht in: | Gynecological endocrinology 2023-12, Vol.39 (1), p.2205952-2205952 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2205952 |
|---|---|
| container_issue | 1 |
| container_start_page | 2205952 |
| container_title | Gynecological endocrinology |
| container_volume | 39 |
| creator | Fernández-Sánchez, M. Fatemi, H. García-Velasco, J. A. Heiser, P. W. Daftary, G. S. Mannaerts, B. |
| description | To determine the incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders (25-35 follicles with a diameter of ≥12 mm on day of triggering) who received a gonadotropin-releasing hormone (GnRH) agonist to trigger final follicular maturation.
We used individual data from women who participated in four different clinical trials and were high responders to ovarian stimulation in a GnRH antagonist protocol in this retrospective combined analysis. All women were evaluated for signs and symptoms of OHSS using identical criteria based on Golan's system (1989).
High responders (n = 77) were of different ethnicities. There were no differences in baseline characteristics between women with or without signs and symptoms of OHSS. Mean ± standard deviation baseline data were: age, 32.3 ± 3.5 years; anti-Müllerian hormone, 42.4 ± 20.7 pmol/L; antral follicle count, 21.5 ± 9.2. Before triggering, duration of stimulation was 9.5 ± 1.6 days and the mean number of follicles with a diameter of ≥12 mm and ≥17 mm was 26.5 ± 4.4 and 8.8 ± 4.7, respectively. Mean serum estradiol (17,159 pmol/l) and progesterone (5.1 nmol/l) levels were high at 36 h after triggering. Overall, 17/77 high responders (22%) developed signs and symptoms of mild OHSS which lasted 6-21 days. The most frequently prescribed medication was cabergoline to prevent worsening of OHSS. No severe OHSS occurred and no OHSS cases were reported as serious adverse events.
High responders receiving GnRH agonist for triggering should be informed that they may experience signs and symptoms of mild OHSS. |
| doi_str_mv | 10.1080/09513590.2023.2205952 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_proquest_miscellaneous_2811566631</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a295821f3cdd434ba4cf59d4f7e0a2a3</doaj_id><sourcerecordid>2811566631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-5639b403860dd369a71e14e5281cc0fa310b258793a91608e16f45d336c284833</originalsourceid><addsrcrecordid>eNp9kc1u1DAURiMEokPhEUBWV-0ig39iJ9mBKuiMVKkShbV1x77JuErsYGeKhkfiKfEw0y5ZWbLO911fn6J4z-iS0YZ-pK1kQrZ0ySkXS86pbCV_USxYVYuS1kq9LBYHpjxAZ8WblB4oZaKq-eviTNRMKq7Eoviz9sZZ9AYJeEsSPmJ0856EjoRHiA482e4njGl2426A2QVP0t7bGEYkl3er-_sr4jLj-i2JmKbgbYYJdDNG0gcPNswxTM6XEQeE5HxPtiGOwef4jf-2uiKQMZdmMkfX9zmV6y66iPgbSxiGCwLTFAOY7dviVQdDwnen87z48fXL9-tVeXt3s77-fFuaqm7nUirRbioqGkWtFaqFmiGrUPKGGUM7EIxuuGzqVkDLFG2Qqa6SVghleFM1QpwX62OvDfCgp-hGiHsdwOl_FyH2GuLszIAaeCsbzjphrK1EtYHKdLK1VVcjBQ6HrstjV17h5w7TrEeXDA4DeAy7pPOjsgmlBMuoPKImhpQids-jGdUH5fpJuT4o1yflOffhNGK3GdE-p54cZ-DTEXC-yz8Pv0IcrJ5hP4TYRcj-kxb_n_EXnz-8Dw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2811566631</pqid></control><display><type>article</type><title>Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><creator>Fernández-Sánchez, M. ; Fatemi, H. ; García-Velasco, J. A. ; Heiser, P. W. ; Daftary, G. S. ; Mannaerts, B.</creator><creatorcontrib>Fernández-Sánchez, M. ; Fatemi, H. ; García-Velasco, J. A. ; Heiser, P. W. ; Daftary, G. S. ; Mannaerts, B.</creatorcontrib><description>To determine the incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders (25-35 follicles with a diameter of ≥12 mm on day of triggering) who received a gonadotropin-releasing hormone (GnRH) agonist to trigger final follicular maturation.
We used individual data from women who participated in four different clinical trials and were high responders to ovarian stimulation in a GnRH antagonist protocol in this retrospective combined analysis. All women were evaluated for signs and symptoms of OHSS using identical criteria based on Golan's system (1989).
High responders (n = 77) were of different ethnicities. There were no differences in baseline characteristics between women with or without signs and symptoms of OHSS. Mean ± standard deviation baseline data were: age, 32.3 ± 3.5 years; anti-Müllerian hormone, 42.4 ± 20.7 pmol/L; antral follicle count, 21.5 ± 9.2. Before triggering, duration of stimulation was 9.5 ± 1.6 days and the mean number of follicles with a diameter of ≥12 mm and ≥17 mm was 26.5 ± 4.4 and 8.8 ± 4.7, respectively. Mean serum estradiol (17,159 pmol/l) and progesterone (5.1 nmol/l) levels were high at 36 h after triggering. Overall, 17/77 high responders (22%) developed signs and symptoms of mild OHSS which lasted 6-21 days. The most frequently prescribed medication was cabergoline to prevent worsening of OHSS. No severe OHSS occurred and no OHSS cases were reported as serious adverse events.
High responders receiving GnRH agonist for triggering should be informed that they may experience signs and symptoms of mild OHSS.</description><identifier>ISSN: 0951-3590</identifier><identifier>EISSN: 1473-0766</identifier><identifier>DOI: 10.1080/09513590.2023.2205952</identifier><identifier>PMID: 37156263</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Adult ; Chorionic Gonadotropin - therapeutic use ; Female ; female infertility ; Fertilization in Vitro - methods ; freeze-all approach ; GnRH agonist triggering ; Gonadotropin-Releasing Hormone ; hCG ; high responders ; Humans ; Incidence ; NCT01856110 ; NCT01956123 ; NCT03228680 ; NCT03296527 ; OHSS ; Ovarian Hyperstimulation Syndrome - epidemiology ; Ovarian Hyperstimulation Syndrome - etiology ; Ovarian Hyperstimulation Syndrome - prevention & control ; ovarian stimulation ; Ovulation Induction - adverse effects ; Ovulation Induction - methods ; Pregnancy ; Pregnancy Rate ; preventive measures ; Retrospective Studies ; Risk of OHSS ; triptorelin</subject><ispartof>Gynecological endocrinology, 2023-12, Vol.39 (1), p.2205952-2205952</ispartof><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-5639b403860dd369a71e14e5281cc0fa310b258793a91608e16f45d336c284833</citedby><cites>FETCH-LOGICAL-c479t-5639b403860dd369a71e14e5281cc0fa310b258793a91608e16f45d336c284833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/09513590.2023.2205952$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/09513590.2023.2205952$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,2096,27479,27901,27902,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37156263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fernández-Sánchez, M.</creatorcontrib><creatorcontrib>Fatemi, H.</creatorcontrib><creatorcontrib>García-Velasco, J. A.</creatorcontrib><creatorcontrib>Heiser, P. W.</creatorcontrib><creatorcontrib>Daftary, G. S.</creatorcontrib><creatorcontrib>Mannaerts, B.</creatorcontrib><title>Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach</title><title>Gynecological endocrinology</title><addtitle>Gynecol Endocrinol</addtitle><description>To determine the incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders (25-35 follicles with a diameter of ≥12 mm on day of triggering) who received a gonadotropin-releasing hormone (GnRH) agonist to trigger final follicular maturation.
We used individual data from women who participated in four different clinical trials and were high responders to ovarian stimulation in a GnRH antagonist protocol in this retrospective combined analysis. All women were evaluated for signs and symptoms of OHSS using identical criteria based on Golan's system (1989).
High responders (n = 77) were of different ethnicities. There were no differences in baseline characteristics between women with or without signs and symptoms of OHSS. Mean ± standard deviation baseline data were: age, 32.3 ± 3.5 years; anti-Müllerian hormone, 42.4 ± 20.7 pmol/L; antral follicle count, 21.5 ± 9.2. Before triggering, duration of stimulation was 9.5 ± 1.6 days and the mean number of follicles with a diameter of ≥12 mm and ≥17 mm was 26.5 ± 4.4 and 8.8 ± 4.7, respectively. Mean serum estradiol (17,159 pmol/l) and progesterone (5.1 nmol/l) levels were high at 36 h after triggering. Overall, 17/77 high responders (22%) developed signs and symptoms of mild OHSS which lasted 6-21 days. The most frequently prescribed medication was cabergoline to prevent worsening of OHSS. No severe OHSS occurred and no OHSS cases were reported as serious adverse events.
High responders receiving GnRH agonist for triggering should be informed that they may experience signs and symptoms of mild OHSS.</description><subject>Adult</subject><subject>Chorionic Gonadotropin - therapeutic use</subject><subject>Female</subject><subject>female infertility</subject><subject>Fertilization in Vitro - methods</subject><subject>freeze-all approach</subject><subject>GnRH agonist triggering</subject><subject>Gonadotropin-Releasing Hormone</subject><subject>hCG</subject><subject>high responders</subject><subject>Humans</subject><subject>Incidence</subject><subject>NCT01856110</subject><subject>NCT01956123</subject><subject>NCT03228680</subject><subject>NCT03296527</subject><subject>OHSS</subject><subject>Ovarian Hyperstimulation Syndrome - epidemiology</subject><subject>Ovarian Hyperstimulation Syndrome - etiology</subject><subject>Ovarian Hyperstimulation Syndrome - prevention & control</subject><subject>ovarian stimulation</subject><subject>Ovulation Induction - adverse effects</subject><subject>Ovulation Induction - methods</subject><subject>Pregnancy</subject><subject>Pregnancy Rate</subject><subject>preventive measures</subject><subject>Retrospective Studies</subject><subject>Risk of OHSS</subject><subject>triptorelin</subject><issn>0951-3590</issn><issn>1473-0766</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kc1u1DAURiMEokPhEUBWV-0ig39iJ9mBKuiMVKkShbV1x77JuErsYGeKhkfiKfEw0y5ZWbLO911fn6J4z-iS0YZ-pK1kQrZ0ySkXS86pbCV_USxYVYuS1kq9LBYHpjxAZ8WblB4oZaKq-eviTNRMKq7Eoviz9sZZ9AYJeEsSPmJ0856EjoRHiA482e4njGl2426A2QVP0t7bGEYkl3er-_sr4jLj-i2JmKbgbYYJdDNG0gcPNswxTM6XEQeE5HxPtiGOwef4jf-2uiKQMZdmMkfX9zmV6y66iPgbSxiGCwLTFAOY7dviVQdDwnen87z48fXL9-tVeXt3s77-fFuaqm7nUirRbioqGkWtFaqFmiGrUPKGGUM7EIxuuGzqVkDLFG2Qqa6SVghleFM1QpwX62OvDfCgp-hGiHsdwOl_FyH2GuLszIAaeCsbzjphrK1EtYHKdLK1VVcjBQ6HrstjV17h5w7TrEeXDA4DeAy7pPOjsgmlBMuoPKImhpQids-jGdUH5fpJuT4o1yflOffhNGK3GdE-p54cZ-DTEXC-yz8Pv0IcrJ5hP4TYRcj-kxb_n_EXnz-8Dw</recordid><startdate>20231214</startdate><enddate>20231214</enddate><creator>Fernández-Sánchez, M.</creator><creator>Fatemi, H.</creator><creator>García-Velasco, J. A.</creator><creator>Heiser, P. W.</creator><creator>Daftary, G. S.</creator><creator>Mannaerts, B.</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20231214</creationdate><title>Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach</title><author>Fernández-Sánchez, M. ; Fatemi, H. ; García-Velasco, J. A. ; Heiser, P. W. ; Daftary, G. S. ; Mannaerts, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-5639b403860dd369a71e14e5281cc0fa310b258793a91608e16f45d336c284833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Chorionic Gonadotropin - therapeutic use</topic><topic>Female</topic><topic>female infertility</topic><topic>Fertilization in Vitro - methods</topic><topic>freeze-all approach</topic><topic>GnRH agonist triggering</topic><topic>Gonadotropin-Releasing Hormone</topic><topic>hCG</topic><topic>high responders</topic><topic>Humans</topic><topic>Incidence</topic><topic>NCT01856110</topic><topic>NCT01956123</topic><topic>NCT03228680</topic><topic>NCT03296527</topic><topic>OHSS</topic><topic>Ovarian Hyperstimulation Syndrome - epidemiology</topic><topic>Ovarian Hyperstimulation Syndrome - etiology</topic><topic>Ovarian Hyperstimulation Syndrome - prevention & control</topic><topic>ovarian stimulation</topic><topic>Ovulation Induction - adverse effects</topic><topic>Ovulation Induction - methods</topic><topic>Pregnancy</topic><topic>Pregnancy Rate</topic><topic>preventive measures</topic><topic>Retrospective Studies</topic><topic>Risk of OHSS</topic><topic>triptorelin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fernández-Sánchez, M.</creatorcontrib><creatorcontrib>Fatemi, H.</creatorcontrib><creatorcontrib>García-Velasco, J. A.</creatorcontrib><creatorcontrib>Heiser, P. W.</creatorcontrib><creatorcontrib>Daftary, G. S.</creatorcontrib><creatorcontrib>Mannaerts, B.</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Gynecological endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fernández-Sánchez, M.</au><au>Fatemi, H.</au><au>García-Velasco, J. A.</au><au>Heiser, P. W.</au><au>Daftary, G. S.</au><au>Mannaerts, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach</atitle><jtitle>Gynecological endocrinology</jtitle><addtitle>Gynecol Endocrinol</addtitle><date>2023-12-14</date><risdate>2023</risdate><volume>39</volume><issue>1</issue><spage>2205952</spage><epage>2205952</epage><pages>2205952-2205952</pages><issn>0951-3590</issn><eissn>1473-0766</eissn><abstract>To determine the incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders (25-35 follicles with a diameter of ≥12 mm on day of triggering) who received a gonadotropin-releasing hormone (GnRH) agonist to trigger final follicular maturation.
We used individual data from women who participated in four different clinical trials and were high responders to ovarian stimulation in a GnRH antagonist protocol in this retrospective combined analysis. All women were evaluated for signs and symptoms of OHSS using identical criteria based on Golan's system (1989).
High responders (n = 77) were of different ethnicities. There were no differences in baseline characteristics between women with or without signs and symptoms of OHSS. Mean ± standard deviation baseline data were: age, 32.3 ± 3.5 years; anti-Müllerian hormone, 42.4 ± 20.7 pmol/L; antral follicle count, 21.5 ± 9.2. Before triggering, duration of stimulation was 9.5 ± 1.6 days and the mean number of follicles with a diameter of ≥12 mm and ≥17 mm was 26.5 ± 4.4 and 8.8 ± 4.7, respectively. Mean serum estradiol (17,159 pmol/l) and progesterone (5.1 nmol/l) levels were high at 36 h after triggering. Overall, 17/77 high responders (22%) developed signs and symptoms of mild OHSS which lasted 6-21 days. The most frequently prescribed medication was cabergoline to prevent worsening of OHSS. No severe OHSS occurred and no OHSS cases were reported as serious adverse events.
High responders receiving GnRH agonist for triggering should be informed that they may experience signs and symptoms of mild OHSS.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>37156263</pmid><doi>10.1080/09513590.2023.2205952</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0951-3590 |
| ispartof | Gynecological endocrinology, 2023-12, Vol.39 (1), p.2205952-2205952 |
| issn | 0951-3590 1473-0766 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2811566631 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals |
| subjects | Adult Chorionic Gonadotropin - therapeutic use Female female infertility Fertilization in Vitro - methods freeze-all approach GnRH agonist triggering Gonadotropin-Releasing Hormone hCG high responders Humans Incidence NCT01856110 NCT01956123 NCT03228680 NCT03296527 OHSS Ovarian Hyperstimulation Syndrome - epidemiology Ovarian Hyperstimulation Syndrome - etiology Ovarian Hyperstimulation Syndrome - prevention & control ovarian stimulation Ovulation Induction - adverse effects Ovulation Induction - methods Pregnancy Pregnancy Rate preventive measures Retrospective Studies Risk of OHSS triptorelin |
| title | Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T03%3A12%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20and%20severity%20of%20ovarian%20hyperstimulation%20syndrome%20(OHSS)%20in%20high%20responders%20after%20gonadotropin-releasing%20hormone%20(GnRH)%20agonist%20trigger%20in%20%22freeze-all%22%20approach&rft.jtitle=Gynecological%20endocrinology&rft.au=Fern%C3%A1ndez-S%C3%A1nchez,%20M.&rft.date=2023-12-14&rft.volume=39&rft.issue=1&rft.spage=2205952&rft.epage=2205952&rft.pages=2205952-2205952&rft.issn=0951-3590&rft.eissn=1473-0766&rft_id=info:doi/10.1080/09513590.2023.2205952&rft_dat=%3Cproquest_doaj_%3E2811566631%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2811566631&rft_id=info:pmid/37156263&rft_doaj_id=oai_doaj_org_article_a295821f3cdd434ba4cf59d4f7e0a2a3&rfr_iscdi=true |